curATime

Shaping the future

of cardiovascular
medicine

curATime

Cluster for atherothrombosis and individualized medicine

A consortium of leading partners from academia and industry is working together to redefine the treatment of cardiovascular diseases. Using artificial intelligence, we identify disease-relevant factors and develop precision medicine approaches that reduce the risk, impact and mortality associated with cardiovascular diseases. Since 2026, our BMFTR-funded cluster is successfully in its second implementation phase.
more about us
  • 13 Projects
  • 37 Partners
  • 61 Participants
  • 45 Publications
News and Events

  • We welcome our new partner

    Advancing personalized treatment after myocardial infarction

    In the curAInfarct project, Prof. Dr. med. Eberhard Wieland and Lucia Thelen from Bioscientia Healthcare GmbH contribute their expertise in laboratory medicine and clinical diagnostics to the curATime consortium.

    The project aims to improve our understanding of the biological processes following myocardial infarction and to support the development of more precise diagnostic and therapeutic approaches. Bioscientia’s experience in laboratory-based analyses and quality-assured diagnostic processes will help translate scientific findings into clinically relevant insights.

    By connecting cardiovascular research with laboratory diagnostics, the collaboration contributes to the long-term goal of identifying individual disease patterns, assessing risks more accurately, and enabling more personalized care for patients after myocardial infarction.

    We warmly welcome Bioscientia to the curATime consortium and look forward to jointly advancing innovative solutions for cardiovascular medicine.

  • New curATime publication

    The systematic review by Aida Romano-Matinez from the working group of Philipp Wild from the University Medical Center Mainz and co-workers shows how AI could help automate echocardiographic analysis, streamline clinical workflows, and ultimately support more efficient cardiovascular care.

  • curATalk Christoph Sandmann - 17.11.2026

    Cells of the Human Heart from Birth to Adulthood: Implications for Cardiac Regeneration

    17.11.2026, 17 - 18

    Dr. Dr. Christoph Sandmann

    Research Fellow at Harvard Medical School, Boston, MA, USA

    The seminar will be held on-site at University Medical Center Mainz, Seminar room 2, Building 708.

  • We are welcoming our new partners

    In the curAIAlert project, Philipp Busch of Mind Games and Daniel Dürr, a cardiac surgeon at the University Medical Center Mainz, are collaborating on the development of an AI-powered wearable warning system for heart failure patients. By combining data from wearables, medical records, and patient-reported outcomes, the system aims to detect early signs of deterioration and enable timely interventions.

    Drawing on its expertise in gamification and serious games, Mind Games will help create engaging features that promote treatment adherence and healthier lifestyles.

    We warmly welcome Mind Games to the curATime consortium and look forward to jointly advancing innovative solutions for heart failure care.

  • curATalk Steffen Massberg - 29.09.2026

    Crosstalk of immunity and thrombosis – novel targets for vascular disease and beyond

    29.09.2026, 17 - 18

    Prof. Dr. med. Steffen Massberg

    Director of the Medical Clinic and Polyclinic I, LMU University Hospital, Munich

    The seminar will be held on-site at University Medical Mainz, Seminar room 2, Building 708.

Show all entries
Our vision

By bringing together powerful players from science and industry with complementary skills, we are meeting the challenge of tailoring the treatment of atherothrombosis-related cardiovascular diseases.

In curATime, we want to use artificial intelligence to identify disease-relevant factors that link to causes of atherothrombosis. Furthermore, we want to identify molecularly defined precision interventions and hope that by applying these we will be able to reduce the incidence and impact of cardiovascular diseases and therefore to significantly reduce mortality in the population.

Highlights from our kick-off event for the second funding phase

On September 9, 2026, we gathered in Kaiserslautern to officially launch the second phase. For more information, see our Past Events section.

Kaiserslautern September 08 2026
The challenge

  • Atherothrombosis is the world's No. 1 cause of death

  • Death rates continue to rise every year

  • In addition to the high mortality rate, cardiovascular diseases can severely impair the quality of life of those affected by it.

  • No significant progress has been made in medical research in recent decades

There is an urgent need for new, personalized therapy options

Our solution

Precise targeting of disease-relevant mechanisms through AI- and mRNA-based technologies.

For this purpose, individualized and subgroup-specific profiles for atherosclerotic biomarkers and risks will be developed using AI-supported and state-of-the-art bioinformatics. The findings will be used to develop innovative diagnostic, preventive and therapeutic concepts. This includes the generation of novel algorithms to improve therapy selection and risk assessment as well as eHealth apps and smart devices. Central to the success of the cluster are large data sets from representative population studies and their computer-based analysis using artificial intelligence.

Precise targeting
curATime at a glance